Literature DB >> 30145797

Validation of the MDS clinical diagnostic criteria for Parkinson's disease.

Ronald B Postuma1, Werner Poewe2, Irene Litvan3, Simon Lewis4, Anthony E Lang5, Glenda Halliday4, Christopher G Goetz6, Piu Chan7, Elizabeth Slow5, Klaus Seppi2, Eva Schaffer8, Silvia Rios-Romenets1, Taomian Mi7, Corina Maetzler8, Yuan Li7, Beatrice Heim2, Ian O Bledsoe9, Daniela Berg8.   

Abstract

BACKGROUND: In 2015, the International Parkinson and Movement Disorder Society published clinical diagnostic criteria for Parkinson's disease. These criteria aimed to codify/reproduce the expert clinical diagnostic process and to help standardize diagnosis in research and clinical settings. Their accuracy compared with expert clinical diagnosis has not been tested. The objectives of this study were to validate the International Parkinson and Movement Disorder Society diagnostic criteria against a gold standard of expert clinical diagnosis, and to compare concordance/accuracy of the International Parkinson and Movement Disorder Society criteria to 1988 United Kingdom Brain Bank criteria.
METHODS: From 8 centers, we recruited 626 parkinsonism patients (434 PD, 192 non-PD). An expert neurologist diagnosed each patient as having PD or non-PD, regardless of International Parkinson and Movement Disorder Society criteria (gold standard, clinical diagnosis). Then a second neurologist evaluated the presence/absence of each individual item from the International Parkinson and Movement Disorder Society criteria. The overall accuracy/concordance rate, sensitivity, and specificity of the International Parkinson and Movement Disorder Society criteria compared with the expert gold standard were calculated.
RESULTS: Of 434 patients diagnosed with PD, 94.5% met the International Parkinson and Movement Disorder Society criteria for probable PD (5.5% false-negative rate). Of 192 non-PD patients, 88.5% were identified as non-PD by the criteria (11.5% false-positive rate). The overall accuracy for probable PD was 92.6%. In addition, 59.3% of PD patients and only 1.6% of non-PD patients met the International Parkinson and Movement Disorder Society criteria for clinically established PD. In comparison, United Kingdom Brain Bank criteria had lower sensitivity (89.2%, P = 0.008), specificity (79.2%, P = 0.018), and overall accuracy (86.4%, P < 0.001). Diagnostic accuracy did not differ according to age or sex. Specificity improved as disease duration increased.
CONCLUSIONS: The International Parkinson and Movement Disorder Society criteria demonstrated high sensitivity and specificity compared with the gold standard, expert diagnosis, with sensitivity and specificity both higher than United Kingdom Brain Bank criteria.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; criteria; diagnosis

Mesh:

Year:  2018        PMID: 30145797     DOI: 10.1002/mds.27362

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  37 in total

1.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

Review 2.  Biomarkers of Parkinson's disease: 20 years later.

Authors:  Rezzak Yilmaz; Franziska Hopfner; Thilo van Eimeren; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2019-04-04       Impact factor: 3.575

3.  The relation between falls risk and movement variability in Parkinson's disease.

Authors:  Steven Morrison; Jacquelyn Moxey; Nick Reilly; Daniel M Russell; Karen M Thomas; Alex A Grunsfeld
Journal:  Exp Brain Res       Date:  2021-04-29       Impact factor: 1.972

4.  [123I]Metaiodobenzylguanidine (MIBG) Cardiac Scintigraphy and Automated Classification Techniques in Parkinsonian Disorders.

Authors:  Susanna Nuvoli; Angela Spanu; Mario Luca Fravolini; Francesco Bianconi; Silvia Cascianelli; Giuseppe Madeddu; Barbara Palumbo
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 5.  Structural Imaging in Parkinson's Disease: New Developments.

Authors:  Stéphane Prange; Elise Metereau; Stéphane Thobois
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-18       Impact factor: 5.081

6.  Cellular senescence in aging and age-related diseases: Implications for neurodegenerative diseases.

Authors:  Erin O Wissler Gerdes; Yi Zhu; B Melanie Weigand; Utkarsh Tripathi; Terence C Burns; Tamar Tchkonia; James L Kirkland
Journal:  Int Rev Neurobiol       Date:  2020-08-11       Impact factor: 3.230

Review 7.  Evolving concepts on bradykinesia.

Authors:  Matteo Bologna; Giulia Paparella; Alfonso Fasano; Mark Hallett; Alfredo Berardelli
Journal:  Brain       Date:  2020-03-01       Impact factor: 13.501

8.  The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review.

Authors:  Vanessa Pitz; Naveed Malek; Edward S Tobias; Katherine A Grosset; Steve Gentleman; Donald G Grosset
Journal:  Mov Disord Clin Pract       Date:  2020-01-07

Review 9.  Challenges in the diagnosis of Parkinson's disease.

Authors:  Eduardo Tolosa; Alicia Garrido; Sonja W Scholz; Werner Poewe
Journal:  Lancet Neurol       Date:  2021-05       Impact factor: 44.182

10.  Association of Stress-Health Factors among Parkinson's Disease Patient/Caregiving-Partner Dyads.

Authors:  Kala M Phillips; Chelsea Siwik; Allison Rodgers; Paul Salmon; Irene Litvan; Megan E Jablonski; J Vincent Filoteo; Elizabeth Cash; Sandra E Sephton
Journal:  Arch Clin Neuropsychol       Date:  2022-01-17       Impact factor: 2.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.